Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

D0500000

Desipramine hydrochloride

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H22N2 · HCl
CAS Number:
58-28-6
Molecular Weight:
302.84
MDL number:
MFCD00058108
UNSPSC Code:
41116107
PubChem Substance ID:
329798614
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

desipramine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Cl[H].CNCCCN1c2ccccc2CCc3ccccc13

InChI

1S/C18H22N2.ClH/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20;/h2-5,7-10,19H,6,11-14H2,1H3;1H

InChI key

XAEWZDYWZHIUCT-UHFFFAOYSA-N

Gene Information

human ... SLC6A2(6530)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Desipramine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Richard M O'Connor et al.
Pharmacology, biochemistry, and behavior, 103(3), 561-567 (2012-10-13)
The neurotransmitter glutamate is increasingly being implicated as playing a role in the molecular pathology underlying depression. The group III family of metabotropic glutamate (mGlu) receptors (mGlu(4,) mGlu(7) and mGlu(8) receptors) remains the most poorly investigated of all glutamate receptors
O F O'Leary et al.
Neuroscience, 228, 36-46 (2012-10-17)
Approximately 50% of patients with a major depressive episode fail to achieve remission with first-line antidepressant treatments. Second-line treatment strategies for such patients include lithium augmentation of antidepressants, particularly with tricyclic antidepressants. The neurobiological mechanisms underlying the therapeutic effects of
Thomas M Polasek et al.
British journal of clinical pharmacology, 75(4), 1019-1028 (2012-08-29)
To determine the effect of increasing adult age on predicted metabolic drug clearance. Predicted metabolic drug clearances (CLPT ) were determined using in vitro-in vivo extrapolation coupled with physiological-based pharmacokinetic modelling and simulation (IVIVE-PBPK) in Simcyp®. Simulations were conducted using
Maria Stratinaki et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(20), 8254-8259 (2013-05-01)
Regulator of G protein signaling 4 (Rgs4) is a signal transduction protein that controls the function of monoamine, opiate, muscarinic, and other G protein-coupled receptors via interactions with Gα subunits. Rgs4 is expressed in several brain regions involved in mood
Aaron Kucinski et al.
Behavioural brain research, 282, 155-164 (2015-01-18)
Falls in patients with Parkinson's disease (PD) are a major and levodopa-unresponsive source of morbidity. We previously described an animal model of falls resulting from impairments in attentional-motor interactions. Reproducing the multisystem dopaminergic-cholinergic cell loss in patients with a history
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service